Jalaja Potluri

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

March, 2025

Jalaja Potluri

Jan 13, 2025, 09:56 | Science

Naveen Pemmaraju: Navitoclax BCLxL Inhibition in patients with myelofibrosis

Naveen Pemmaraju, Professor at the Department of Leukemia at MD Anderson Cancer Center, shared a…

Dec 23, 2024, 11:55 | Drugs

Talha Badar: Venetoclax and Azacitidine for elderly AML ineligible for intensive Induction

Talha Badar shared on X: “Brief overview of venetoclax+azacitidine for elderly AML ineligible for intensive…

Dec 6, 2024, 15:22 | Insight

The impact of post-remission G-CSF use in the phase 3 studies of venetoclax in AML

Mohamed Benlazar, Professor of Hematology at Sidi Bel Abbès University Hospital, shared a post on…

Aug 19, 2024, 10:07 | Insight

Nicolas Duployez: A 4-gene prognostic model stratified OS outcomes with VEN-AZA treatment in AML

Nicolas Duployez, Molecular Biologist at Lille University Hospital, shared on X about a recent paper…

Aug 14, 2024, 07:20 | Drugs

Keith W Pratz: Novel risk signature for AML treated with Azacitidine and Venetoclax

Keith W Pratz, Director of Leukemia at the Hospital of University of Pennsylvania, shared on…

All: 5 Posts: 1 - 100

'

King Charles III Hospitalized Following Side Effects from Cancer Treatment

'

Keith T. Flaherty has been elected as the AACR President-Elect for 2025-2026

'

MARIPOSA trial results presented at ELCC25 - BREAKING from Paris

'

Miranda McKeon: Battling Breast Cancer at 19, Inspiring Millions on Instagram

'

WHO Takes a Creative Leap in Raising Awareness for Colorectal Cancer

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023